Stock Market & Financial Investment News

News Breaks March 7, 2013 10:42 EDT SRPT Sarepta DMD drug still has accelerated approval potential, says Piper Jaffray Piper Jaffray said it still believes there is a 50/50 chance that Sarepta will be able to file for approval of its Duchenne Muscular Dystrophy drug eteplirsen with its existing data. Piper said that if the company is required to conduct a larger trial prior to filing, a slide in the stock would be likely but would present a buying opportunity. The firm maintains an Overweight rating and $35 price target on Sarepta. News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 11:13 EDT SRPT Sarepta rises after reporting clinical data Subscribe for More Information 09:54 EDT SRPT Sarepta data supports accelerated approval, says Piper Jaffray Subscribe for More Information 08:39 EDT SRPT Sarepta eteplirsen demonstrates benefit on walking test in Phase IIb study Sarepta Therapeutics announced updated data from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy, or DMD. Results at 84 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test. As previously reported, Study 202 met its primary endpoint of increased novel dystrophin as assessed by muscle biopsy at Week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes. Eteplirsen is Sarepta's lead exon-skipping compound in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51. June 17, 2013 12:20 EDT SRPT Options with increasing implied volatility: WLT LNCO SRPT LINE Subscribe for More Information June 14, 2013 11:23 EDT SRPT Options with increasing implied volatility: TWO SRPT LNCO LINE DVA 06:15 EDT SRPT Leerink remains cautious on accelerated approval for Sarepta Subscribe for More Information June 5, 2013 13:29 EDT SRPT Options with decreasing implied volatility: INFI SRPT GES SUPN CPRT Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.